Jonah Feldman

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients with prostate cancer.

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without docetaxel in the metastatic hormone-sensitive prostate cancer setting.

Patient-reported outcomes from DESTINY-Breast06 show trastuzumab deruxtecan improved time to deterioration for pain and other subscores, with no decline in overall QOL in either arm in the HER2 low/ultralow breast cancer setting.

Pembrolizumab is the first agent showing overall survival benefit as adjuvant therapy in renal cell carcinoma, leading oncologists to adopt adjuvant therapy for many of their patients.

In a feature article incorporating Case-Based Roundtable® discussions, we look at the evolution of management for chronic graft-vs-host disease (cGVHD) following allogeneic hematopoietic cell transplantation and the impact of effective non-steroid therapies for cGVHD.

Treatment with ARV-766, an investigational proteolysis targeting chimera (PROTAC) androgen receptor degrader, led to a ≥50% PSA decline in 43% of patients with metastatic castration-resistant prostate cancer.

A retrospective cohort of patients with metastatic urothelial cancer who received prior enfortumab vedotin had low efficacy when treated with sacituzumab govitecan, with the best outcomes coming from direct sequencing the two agents.

In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.

With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.

In this feature, Targeted Oncology spoke to experts in breast cancer treatment on the trends in management of toxicity with the growing drug class of antibody-drug conjugates.

A phase 2 study has begun enrolling patients with 0 to 1 prior lines of therapy to receive the mTOR inhibitor nab-Sirolimus plus letrozole for advanced or recurrent endometrioid carcinoma.

A retrospective study of real-world patients showed that immune engager therapies had the best response and progression-free survival rates in patients with multiple myeloma who had a relapse after idecabtagene vicleucel treatment.

A retrospective study of insurance claims showed patients received ruxolitinib mainly in the second or third line for chronic graft-vs-host disease, with dose adjustment used and no difference shown in time to discontinuation between adult and pediatric patients.

Participants in virtual events discussed the key issue of whether to initiate therapy immediately or wait for test results that could show the best approach in patients with advanced lung cancer.

Oncologists at Allegheny Health Network share updates on their latest approaches for optimizing surgical and systemic treatment in patients with pancreatic cancer.

A post hoc sensitivity analysis that counted use of subsequent therapies in patients censored from primary overall survival follow-up favored darolutamide plus androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer.

The approval of talquetamab, a GPRC5D-targeted bispecific T-cell engager, led to discussions in 2 separate Case-Based Roundtable events on therapy sequencing selection, toxicity, and outpatient treatment.

Durable responses were seen with obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia across bone marrow blast levels, with best efficacy and tolerability in those with less than 5% blasts.

The RELIEVE study looked at real-world patients receiving trastuzumab deruxtecan based on HER2 expression status and time to next treatment including in those whose HER2 status changed during course of treatment.

At 2 separate Case-Based Roundtable events, oncologists discussed important factors that could influence their choice of frontline therapy for a patient with advanced hepatocellular carcinoma.

The role of immunotherapy continues to evolve for the treatment of patients with skin cancer, now with physicians able to choose between the use of single-agent vs dual immunotherapy treatments. In 2 separate Case-Based Roundtable events led by Alan Tan, MD, and Douglas B. Johnson, MD, MSCI, physicians considered these options for a patient with metastatic melanoma.

The OPEB-01 trial showed a potential maintenance role for olaparib, pembrolizumab, and bevacizumab in patients who responded to chemotherapy after platinum-sensitive recurrence to ovarian cancer.

The safety run-in of the LEAP-014 trial showed acceptable toxicity and antitumor responses in patients with metastatic esophageal cancer receiving pembrolizumab, lenvatinib, and chemotherapy consisting of cisplatin plus either paclitaxel or 5-fluororacil.

Results from the BRUIN study focusing on patients with chronic lymphocytic leukemia/small lymphocytic lymphoma showed benefit in patients were pretreated with Bruton tyrosine kinase inhibitors.

For Leukemia Awareness Month, Salman Fazal, MD, and Tibor Kovacsovics, MD, discussed the importance of biomarker testing and targeting in diagnosis, prognosis, and treatment of acute myeloid leukemia.

Investigators reported the best objective response, progression-free survival, overall survival, and safety of a B7-H3–directed antibody-drug conjugate at the 2023 World Conference on Lung Cancer.

Advances are being seen with the introduction of Menin inhibitors

Triplet therapy regimens now are on the horizon for patients with AML, thanks to ongoing research into targeted therapies.